Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Medios exceeds half‑year revenue of €1bn for first time, but lowers EBITDA forecast

Medios increased revenue in the first half of 2026 by 8.4% to €1.075bn, reaching a half‑year revenue above €1bn for the first time. Despite the revenue growth, EBITDA pre fell 5.1% to €44m and the EBITDA‑pre margin dropped to 4.1%, prompting the company to cut its profit forecast for 2026. Operating cash flow was halved to €11.2m, partly due to timing effects in tax payments. Medios acquired a 74% stake in Caelo for €9.4m and raised its revenue forecast for 2026, but expects continued margin pressure and savings from the Avanti‑Medios! program. » Mere på de.investing.com
Medios acquires 74% of Caesar & Loretz and moves into the German active-ingredient market

Medios is buying 74 percent of Caesar & Loretz GmbH (Caelo), based in Hilden; the transaction is expected to close in the fourth quarter of 2026. Caelo is projected to generate around €40 million in revenue in 2026, roughly 2% of Medios’s planned revenue, but primarily serves as a door opener for entry into the market for pharmaceutical active and auxiliary substances. Medios is likely to consider further internal or external measures to strengthen this area; Q2 figures will be published tomorrow after the profit target for 2026 was already lowered. » Mere på finanzen.net
Medios acquires 74 percent of Caelo and confirms annual forecast

Medios purchases 74 percent of Caesar & Loretz (Caelo); the credit‑financed purchase price is in the upper single‑digit millions and depends on future performance. Caelo expects revenue of around €40 million for 2026 and will be fully consolidated after closing. Completion is subject to market‑standard conditions and is expected in Q4 2026; the takeover has no impact on the annual forecast. Investor reaction: Medios share initially rose by about 1 percent. » Mere på finanzen.net

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har Medios allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde Medios en omsætning på 547,31 mio. € og et nettoresultat på 3,54 mio. €

(EUR)	juni 2026	YoY
Omsætning	547,31 mio.	7,94 %
Bruttofortjeneste	20,11 mio.	12,51 %
Nettoresultat	3,54 mio.	43,75 %
EBITDA	19,46 mio.	5,39 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	258,9 mio. €
Antal aktier	24,8 mio.
Højeste/laveste i 52 uger	20,60 € - 10,44 €
Udbytte	Nej
Beta	1,26
P/E (PE Ratio)	23,45
PEG (PEG Ratio)	-0,58
K/I (PB Ratio)	0,48
P/S (PS Ratio)	0,12

Virksomhedsprofil

Die Medios AG ist zusammen mit ihren Tochtergesellschaften im Großhandel mit Spezialarzneimitteln in Deutschland tätig. Das Unternehmen ist in den Segmenten Pharmazeutische Versorgung und Patientenspezifische Therapien tätig. Das Segment Pharmazeutische Versorgung bietet Produkte für die Bereiche Onkologie, Neurologie, Autoimmunologie, Augenheilkunde, Infektiologie und Hämophilie an. Das Segment Patientenspezifische Therapien stellt Medikamente für Patienten im Auftrag von Apotheken her und bietet patientenindividuelle Therapien zur Abgabe von individuell dosierten Tabletten an. Das Unternehmen wurde 2016 gegründet und hat seinen Sitz in Berlin, Deutschland.